The epidemiological impact of viral diseases, combined with the emergence and reemergence
of some viruses, and the difficulties in identifying effective therapies, have encouraged
several studies to develop new therapeutic strategies for viral infections. In this context, the use of immunotherapy
for the treatment of viral diseases is increasing. One of the strategies of immunotherapy
is the use of antibodies, particularly the monoclonal antibodies (mAbs) and multi-specific antibodies,
which bind directly to the viral antigen and bring about activation of the immune system. With current
advancements in science and technology, several such antibodies are being tested, and some are already
approved and are undergoing clinical trials. The present work aims to review the status of mAb
development for the treatment of viral diseases.
